Main Street Group’s ImmunityBio IBRX Stock Holding History

Main Street Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$788	Hold	90	–	–	﹤0.01%	767
2026 Q1	$690	Buy	+90	New	+$616	﹤0.01%	778
2025 Q4	–	Sell	-90	Closed	-$221	–	325
2025 Q3	$221	Buy	90 +39	+76%	+$100	﹤0.01%	768
2025 Q2	$135	Buy	+51	New	+$137	﹤0.01%	756

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Main Street Group's IBRX Position: Q2 2026 in Review

Main Street Group held its ImmunityBio (IBRX) position steady in Q2 2026 at 90 shares worth $788. The position accounts for ﹤0.01% of the portfolio, ranked #767.

Main Street Group first reported a position in IBRX in Q2 2025 and has held it in 4 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Main Street Group held 90 shares of ImmunityBio worth $788 as of Q2 2026.
Main Street Group left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up ﹤0.01% of Main Street Group's portfolio in Q2 2026, its #767 holding.
Main Street Group first reported a position in ImmunityBio in Q2 2025 and has held it in 4 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Main Street Group's 13F filing for Q2 2026, filed 13 Jul 2026.